Edition:
United Kingdom

Sihuan Pharmaceutical Holdings Group Ltd (0460.HK)

0460.HK on Hong Kong Stock

1.42HKD
16 Aug 2019
Change (% chg)

HK$0.02 (+1.43%)
Prev Close
HK$1.40
Open
HK$1.39
Day's High
HK$1.44
Day's Low
HK$1.38
Volume
7,035,000
Avg. Vol
12,403,925
52-wk High
HK$2.22
52-wk Low
HK$1.24

Latest Key Developments (Source: Significant Developments)

Sihuan Pharmaceutical Holdings' Unit Establishes JV With Strides Pharma Global
Monday, 29 Jul 2019 

July 29 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::UNIT ESTABLISHES JOINT VENTURE WITH STRIDES PHARMA GLOBAL PTE LIMITED.JOINT VENTURE WILL BE PRINCIPALLY ENGAGED IN BUSINESS OF REGISTRATION AND SALES FOR DRUGS.JOINT VENTURE IS OWNED AS TO 51% AND 49% BY UNIT AND STRIDES PHARMA GLOBAL PTE RESPECTIVELY.  Full Article

Sihuan Pharmaceutical Holdings Sees HY Net Loss
Friday, 19 Jul 2019 

July 19 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::EXPECTED TO RECORD A NET LOSS FOR SIX MONTHS ENDED 30 JUNE 2019.EXPECTED RESULT DUE TO POSSIBLE IMPAIRMENT LOSS ON GOODWILL OF APPROXIMATELY RMB2.84 BILLION.  Full Article

Sihuan Pharmaceutical Holdings Group's Two Drugs Get Registration Approval In PRC
Sunday, 16 Jun 2019 

June 17 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::GETS DRUG REGISTRATION APPROVAL BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC FOR TWO DRUGS.  Full Article

Sihuan Pharmaceutical Gets Clinical Trial Approval For Third Generation Of EGFR Inhibitor Xzp-5809
Tuesday, 28 May 2019 

May 29 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::ACQUIRED PHASE I TO III CLINICAL TRIAL APPROVAL FOR THIRD GENERATION OF EGFR INHIBITOR XZP-5809.  Full Article

Sihuan Pharma Holdings FY Profit Attributable Up 11.8 Pct
Monday, 18 Mar 2019 

March 19 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::PROFIT ATTRIBUTABLE TO OWNERS OF COMPANY INCREASED BY 11.8% TO RMB1,620.0 MILLION IN 2018.REVENUE OF GROUP INCREASED BY 6.2% FROM RMB2,745.8 MILLION TO RMB2,917.4 MILLION IN 2018.RECOMMENDS DECLARATION AND PAYMENT OF A FINAL CASH DIVIDEND OF RMB1.3 CENTS PER SHARE.  Full Article

Sihuan Pharmaceutical Holdings Group Says Janagliflozin Commenced Phase III Clinical Trial In China
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::FIRST ANTI-DIABETIC INNOVATIVE PATENTED NEW DRUG JANAGLIFLOZIN COMMENCED PHASE III CLINICAL TRIAL IN CHINA.  Full Article

Sihuan Pharmaceutical Says National Medical Products Administration Of China Grants Approval For Group's Diabetes Drug
Tuesday, 2 Oct 2018 

Oct 2 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA GRANTS APPROVAL FOR GROUP'S DIABETES DRUG METFORMIN HYDROCHLORIDE TABLETS.  Full Article

Sihuan Pharmaceutical's Insulin Analogue Degludec Granted Approval For Clinical Trials
Wednesday, 5 Sep 2018 

Sept 6 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::INSULIN ANALOGUE DEGLUDEC DEVELOPED BY GROUP HAS BEEN GRANTED APPROVAL FOR CLINICAL TRIALS FROM CHINA FDA.  Full Article

Sihuan Pharmaceutical Holdings Group Posts Hy Profit Attributable Of Rmb765.7 Mln
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::HY REVENUE RMB1.28 BILLION VERSUS RMB1.44 BILLION.AN INTERIM DIVIDEND OF RMB0.4 CENTS PER SHARE WAS DECLARED BY BOARD.HY PROFIT ATTRIBUTABLE RMB 765.7 MILLION VERSUS RMB842.5 MILLION A YEAR AGO.  Full Article

Sihuan Pharmaceutical Holdings Group Says Pirotinib Commences Phase II Clinical Trial In China
Monday, 13 Aug 2018 

Aug 13 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd <0460.HK>::PIROTINIB COMMENCED PHASE II CLINICAL TRIAL IN CHINA.  Full Article